ArticleRevista da Associacao Medica Brasileira (1992)2026
MicroRNA-204 and microRNA-652-3p as promising biomarkers for endometrial cancer diagnosis and prognosis.
Article in Revista da Associacao Medica Brasileira (1992), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveEndometrial cancer is the most common gynecologic malignancy in developed countries. Currently, there are no reliable screening methods available for the early diagnosis or prognostic evaluation of the disease. MicroRNAs are small non-coding ribonucleic acid molecules primarily involved in the regulation of gene expression. The aim of this study was to evaluate and compare serum levels of microRNA-204 and microRNA-652-3p between patients diagnosed with endometrial cancer and healthy controls in order to determine their potential diagnostic and prognostic value as candidate biomarkers.
methodsSerum samples were collected from a total of 226 participants, comprising 150 patients diagnosed with endometrial cancer and 76 healthy controls. Relative expression levels of microRNA-204 and microRNA-652-3p were measured using quantitative real-time polymerase chain reaction.
resultsThe present study demonstrated that serum levels of microRNA-204 and microRNA-652-3p were significantly elevated in patients with endometrial cancer compared with healthy controls. Overexpression of these microRNAs was significantly associated with disease stage and adverse prognosis. Moreover, patients with high microRNA-204 and microRNA-652-3p expression exhibited significantly shorter survival than those with low expression. Elevated expression of both microRNAs was also significantly associated with an increased risk of disease recurrence.
conclusionSerum levels of microRNA-204 and microRNA-652-3p distinguished patients with endometrial cancer from healthy controls. In addition, both microRNAs were associated with prognosis, including an increased risk of disease recurrence. These findings require confirmation in larger, independently validated cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.